Skip to main content

Advertisement

Table 2 Surgical and postoperative pathological characteristics, and treatment of the SGC and MGC of the entire cohort (n = 4107) and after propensity score matching (n = 665)

From: Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis

Parameters Entire cohort (before matching) P value Propensity score matched cohort P value
SGC, n (%) MGC, n (%) SGC, n (%) MGC, n (%)
Surgical approach    0.414    0.959
 Open 802 (20.2) 23 (17.3)   93 (17.5) 23 (17.3)  
 Laparoscopic 3172 (79.8) 110 (82.7)   439 (82.5) 110 (82.7)  
Type of gastrectomy    < 0.001    1.000
 Total 2129 (53.6) 106 (79.7)   424 (79.7) 106 (79.7)  
 Distal 1782 (44.8) 27 (20.3)   108 (20.3) 27 (20.3)  
 Proximal 63 (1.6) 0 (0.0)   0 (0.0) 0 (0.0)  
Number of eLNs    0.547    0.514
 ≤ 15 161 (4.1) 4 (3.0)   11 (2.1) 4 (3.0)  
 > 15 3813 (95.9) 129 (97.0)   521 (97.9) 129 (97.0)  
pT stage    0.033    0.706
 T1 983 (24.7) 20 (15.0)   98 (18.4) 20 (15.0)  
 T2 446 (11.2) 17 (12.8)   54 (10.2) 17 (12.8)  
 T3 1165 (29.3) 37 (27.8)   144 (27.1) 37 (27.8)  
 T4a 1380 (34.7) 59 (44.4)   236 (44.4) 59 (44.4)  
pN stage    0.035    0.909
 N0 1442 (36.3) 37 (27.8)   157 (29.5) 37 (27.8)  
 N1 601 (15.1) 16 (12.0)   73 (13.7) 16 (12.0)  
 N2 680 (17.1) 23 (17.3)   86 (16.2) 23 (17.3)  
 N3 1251 (31.5) 57 (42.9)   216 (40.6) 57 (42.9)  
pTNM stage    0.041    0.430
 Stage I 1143 (28.8) 25 (18.8)   123 (23.1) 25 (18.8)  
 Stage II 875 (22.0) 32 (24.1)   107 (20.1) 32 (24.1)  
 Stage III 1956 (49.2) 76 (57.1)   302 (56.8) 76 (57.1)  
Tumor size    0.222    0.843
 ≤ 5 cm 2652 (66.7) 82 (61.7)   323 (60.7) 82 (61.7)  
 > 5 cm 1322 (33.3) 51 (38.3)   209 (39.3) 51 (38.3)  
Tumor histological type    0.640    0.860
 Differentiated 1150 (28.9) 36 (27.1)   140 (26.3) 36 (27.1)  
 Undifferentiated 2824 (71.1) 97 (72.9)   392 (73.7) 97 (72.9)  
Postoperative complications    0.242    0.481
 Absent 3182 (80.1) 101 (75.9)   419 (78.8) 101 (75.9)  
 Present 792 (19.9) 32 (24.1)   113 (21.2) 32 (24.1)  
Adjuvant chemotherapya    0.069    0.852
 No 1263 (42.2) 38 (33.6)   150 (34.6) 38 (33.6)  
 Yes 1728 (57.8) 75 (66.4)   284 (65.4) 75 (66.4)  
  1. SGC solitary gastric cancers, MGC multiple gastric cancers, eLNs examined lymph nodes, pT stage pathological tumor stage, pN stage pathological node stage, pTNM stage pathological tumor-node-metastasis stage
  2. aAdjuvant chemotherapy only patients with advanced gastric cancer were analyzed, which included 3104 patients before matching and 547 after matching